J Cancer 2019; 10(24):6170-6174. doi:10.7150/jca.35917 This issue

Research Paper

Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk

Cheng-Yuan Gu1,2*, Sheng-Ming Jin1,2*, Xiao-Jian Qin1,2, Yao Zhu1,2, Dai Bo1,2, Guo-Wen Lin1,2, Guo-Hai Shi1,2✉, Ding-Wei Ye1,2✉

1. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
*These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Gu CY, Jin SM, Qin XJ, Zhu Y, Bo D, Lin GW, Shi GH, Ye DW. Genetic variants in RTEL1 influencing telomere length are associated with prostate cancer risk. J Cancer 2019; 10(24):6170-6174. doi:10.7150/jca.35917. Available from https://www.jcancer.org/v10p6170.htm

File import instruction


Telomere length measured in lymphocytes has been evaluated as a potential biomarker for prostate cancer (PCa) risk. Identifying genetic variants that affect telomere length and testing their association with disease could clarify any causal role. We therefore investigated associations between genetic variants in three telomere length-related genes and PCa risk in a case-control study. The influence of these variants on the leukocyte telomere lengths was then appraised by real-time PCR. RTEL1 rs2297441 [odds ratio (OR): 1.23; 95% confidence interval (CI): 1.03-1.46, P = 0.021] and rs3208008 (OR: 1.23; 95% CI: 1.03-1.46) were associated with PCa risk. These two risk single nucleotide polymorphisms (SNPs) (OR: 0.59; 95% CI: 0.39-0.89, P = 0.012 and OR: 0.58; 95% CI: 0.38-0.87, P = 0.009, respectively) and another SNP PARP1 rs1136410 (OR: 1.53; 95% CI: 1.01-2.31, P = 0.043) were also associated with leukocyte telomere length. These findings support that genetic determinants of telomere length may influence PCa risk.

Keywords: prostate cancer, polymorphisms, telomere, susceptibility